Verus' Childs' Play Brings in $98 Million A Round

With a goal to focus on pediatric respiratory disease and allergy, several ex-Dura Pharmaceutical executives were able to attract $98 million in Series A funding without having technology, products, or IP. The company's June 2005 financing is another signal that investing in the highest-quality start-up biotechs is increasingly a game for VC firms with deep pockets.

Verus Pharmaceuticals Inc. 's monster $98 million Series A is certainly notable for its size and for the fact that—at the time—Verus boasted no IP, technology, or products. Verus' ability to raise funds to make a serious play in pediatric medicine is also a reminder that despite the proliferation of the specialty pharma model there are still untapped, high-growth niche areas where businesses can be built with few serious competitors, and where a management team with a successful track record can attract big money. And importantly, the June 2005 financing is another signal that investing in the highest quality start-up biotech investments is increasingly a game for VC firms with deep pockets.

The equity portion of the round, totaling $78 million, was led by Domain Associates and Prospect Venture Partners and included...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.